


CLAIMS

1. A 9-arylsulfone of the formula (XII)



where R_3 is:

- 5 (1) -H,
- (2) C_1 - C_4 alkyl,
- (3) C_0 - C_4 - ϕ where the ϕ substituent is optionally substituted with 1 or 2
 - (a) -F, -Cl, -Br, -I,
 - (b) -O- R_{3-1} where R_{3-1} is:
 - 10 -H,
 - C_1 - C_4 alkyl,
 - ϕ ,
 - (c) - CF_3 ,
 - (d) -CO-N $R_{3-2}R_{3-3}$ where R_{3-2} and R_{3-3} are -H and C_1 - C_4 alkyl, and where R_{3-2} and R_{3-3} are taken with the attached nitrogen atom to form a ring selected from the group
 - 15 consisting of 1-pyrrolidinyl, 1-piperazinyl and 1-morpholinyl,
 - (e) -NH-SO $_2$ - R_{3-4} where R_{3-4} is -H and C_1 - C_4 alkyl,
 - (f) -N $R_{3-2}R_{3-3}$ where R_{3-2} and R_{3-3} are as defined above,
 - (g) -N R_{3-4} -CO- R_{3-4} where R_{3-4} is as defined above,
 - 20 (h) -SO $_2$ -N $R_{3-2}R_{3-3}$ where R_{3-2} and R_{3-3} are as defined above,
 - (i) -C \equiv N,
 - (j) -NO $_2$,

where R_N is:

- 25 (1) -H,
- (2) C_1 - C_4 alkyl,
- (3) C_0 - C_4 - ϕ where the ϕ substituent is optionally substituted with 1 or 2
 - (a) -F, -Cl, -Br, -I,
 - (b) -O- R_{N-1} where R_{N-1} is
 - H,

C_1 - C_4 alkyl,

$-\phi$,

(c) $-\text{CF}_3$,

(d) $-\text{CO}-\text{NR}_{N-2}\text{R}_{N-3}$ where R_{N-2} and R_{N-3} are $-\text{H}$ and C_1 - C_4 alkyl, and where
 5 R_{3-2} and R_{3-3} are taken with the attached nitrogen atom to form a ring selected from the group consisting of 1-pyrrolidinyl, 1-piperazinyl and 1-morpholinyl,

(e) $-\text{NH}-\text{SO}_2-\text{R}_{N-4}$ where R_{N-4} is $-\text{H}$ and C_1 - C_4 alkyl,

(f) $-\text{NR}_{N-2}\text{R}_{N-3}$ where R_{N-2} and R_{N-3} are as defined above,

(g) $-\text{NR}_{N-4}-\text{CO}-\text{R}_{N-4}$ where R_{N-4} is as defined above,

10 (h) $-\text{SO}_2-\text{NR}_{N-2}\text{R}_{N-3}$ where R_{N-2} and R_{N-3} are as defined above,

(i) $-\text{C}\equiv\text{N}$,

(j) $-\text{NO}_2$,

where R_X is:

(1) $-\text{H}$

15 (2) $-\text{F}$, $-\text{Cl}$, $-\text{Br}$, $-\text{I}$,

(3) $-\text{O}-\text{R}_{X-1}$ where R_{X-1} is:

$-\text{H}$,

C_1 - C_4 alkyl,

$-\phi$,

20 (4) $-\text{CF}_3$,

(5) $-\text{CO}-\text{NR}_{X-2}\text{R}_{X-3}$ where R_{X-2} and R_{X-3} are as defined above,

(6) $-\text{NH}-\text{SO}_2-\text{R}_{X-4}$ where R_{X-4} is as defined above,

(7) $-\text{NR}_{X-2}\text{R}_{X-3}$ where R_{X-2} and R_{X-3} are as defined above,

(8) $-\text{NR}_{X-4}-\text{CO}-\text{R}_{X-4}$ where R_{X-4} is as defined above,

25 (9) $-\text{SO}_2-\text{NR}_{X-2}\text{R}_{X-3}$ where R_{X-2} and R_{X-3} are as defined above,

(10) $-\text{C}\equiv\text{N}$,

(11) $-\text{NO}_2$;

where R_9 is:

(1) $-\text{H}$,

30 (2) $-\text{F}$, $-\text{Cl}$,

(3) C_1 - C_4 alkyl,

(4) C_1 - C_3 alkoxy,

(5) $-\text{CF}_3$,

(6) C₀-C₄-φ where the -φ substituent is optionally substituted with 1 or 2

(a) -F, -Cl, -Br, -I,

(b) -O-R_{9.1} where R_{9.1} is:

-H,

C₁-C₄ alkyl,

-φ,

(c) -CF₃,

(d) -CO-NR_{9.2}R_{9.3} where R_{9.2} and R_{9.3} are -H and C₁-C₄ alkyl, and where

R_{9.2} and R_{9.3} are taken with the attached nitrogen atom to form a ring selected from the group consisting of 1-pyrrolidinyl, 1-piperazinyl and 1-morpholinyl,

(e) -NH-SO₂-R_{9.4} where R_{9.4} is -H and C₁-C₄ alkyl,

(f) -NR_{9.2}R_{9.3} where R_{9.2} and R_{9.3} are as defined above,

(g) -NR_{9.4}-CO-R_{9.4} where R_{9.4} is as defined above,

(h) -SO₂-NR_{9.2}R_{9.3} where R_{9.2} and R_{9.3} are as defined above,

(i) -C≡N,

(j) -NO₂

(7) -OR_{9.1} where R_{9.1} is as defined above,

(8) -CO-NR_{9.2}R_{9.3} where R_{9.2} and R_{9.3} are as defined above,

(9) -NR_{9.2}R_{9.3} where R_{9.2} and R_{9.3} are as defined above,

(10) -NH-SO₂-R_{9.4} where R_{9.4} is as defined above,

(11) -NH-CO₂-R_{9.2} where R_{9.2} is as defined above and pharmaceutically acceptable salts thereof.

2. A 9-arylsulfone (XII) according to claim 1 where R₃ is selected from the group consisting of -H and C₁-C₂ alkyl.

3. 9-arylsulfone (XII) according to claim 2 where R₃ is -H.

4. A 9-arylsulfone (XII) according to claim 1 where R_N is selected from the group consisting of -H and C₁-C₄ alkyl.

5. A 9-arylsulfone (XII) according to claim 4 where R_N is -H, C₁ alkyl and C₂ alkyl.

6. A 9-arylsulfone (XII) according to claim 1 where R_x is selected from the group consisting of -H, -F and -Cl.
7. A 9-arylsulfone (XII) according to claim 6 where R_x is -H.
8. A 9-arylsulfone (XII) according to claim 1 where R_9 is selected from the group consisting of -H, -F, -Cl, C_1 - C_3 alkyl, C_1 - C_3 alkoxy and $-CF_3$.
9. A 9-arylsulfone (XII) according to claim 8 where R_9 is -H, -F, -Cl, C_1 alkyl, C_1 alkoxy, and $-CF_3$.
10. A 9-arylsulfone (XII) according to claim 8 where the R_9 substituent is in the 3- or 4-position.
11. A 9-arylsulfone (XII) according to claim 1 where the pharmaceutically acceptable salt is selected from the group consisting of salts of methanesulfonic, hydrochloric, hydrobromic, sulfuric, phosphoric, nitric, benzoic, citric, tartaric, fumaric, maleic, $CH_3-(CH_2)_n-COOH$ where n is 0 thru 4, $HOOC-(CH_2)_n-COOH$ where n is as defined above.
12. A 9-arylsulfone (XII) according to claim 11 where the pharmaceutically acceptable salt is selected from the group consisting of salts of hydrochloric, maleate and methanesulfonic acids.
13. A 9-arylsulfone (XII) according to claim 12 where the pharmaceutically acceptable salt is the salt of hydrochloric acid.
14. A 9-arylsulfone (XII) according to claim 1 where the substituted 9-arylsulfone is selected from the group consisting of:
- 9-(phenylsulfonyl)-1,2,3,4,5,6-hexahydroazepino[4,5-b]indole,
 - 9-[(4-fluorophenyl)sulfonyl]-1,2,3,4,5,6-hexahydroazepino[4,5-b]indole,
 - 9-[(4-methylphenyl)sulfonyl]-1,2,3,4,5,6-hexahydroazepino[4,5-b]indole,
 - 9-[(4-methoxyphenyl)sulfonyl]-1,2,3,4,5,6-hexahydroazepino[4,5-b]indole,
 - 9-[(3-fluorophenyl)sulfonyl]-1,2,3,4,5,6-hexahydroazepino[4,5-b]indole,
 - 9-[(3-methoxyphenyl)sulfonyl]-1,2,3,4,5,6-hexahydroazepino[4,5-b]indole,

9-[(4-trifluoromethylphenyl)sulfonyl]-1,2,3,4,5,6-hexahydroazepino[4,5-b]indole,
 6-ethyl-9-(phenylsulfonyl)-1,2,3,4,5,6-hexahydroazepino[4,5-b]indole,
 6-ethyl-9-[(4-fluorophenyl)sulfonyl]-1,2,3,4,5,6-hexahydroazepino[4,5-b]indole,
 6-methyl-9-[(4-fluorophenyl)sulfonyl]-1,2,3,4,5,6-hexahydroazepino[4,5-b]indole,
 5 6-methyl-9-[(4-trifluoromethylphenyl)sulfonyl]-1,2,3,4,5,6-hexahydroazepino[4,5-
 b]indole,
 6-ethyl-9-[(4-trifluoromethylphenyl)sulfonyl]-1,2,3,4,5,6-hexahydroazepino[4,5-
 b]indole and
 6-methyl-9-(phenylsulfonyl)-1,2,3,4,5,6-hexahydroazepino[4,5-b]indole.

10 15. A 9-arylsulfone (XII) according to claim 14 where the substituted 9-arylsulfone is 6-
 methyl-9-(phenylsulfonyl)-1,2,3,4,5,6-hexahydroazepino[4,5-b]indole.

15 16. A 9-arylsulfone (XII) according to claim 1 where the substituted 9-arylsulfone is
 selected from the group consisting of:


9-[(3,4-difluorophenyl)sulfonyl]-1,2,3,4,5,6-hexahydroazepino[4,5-b]indole,
 9-[(3,5-difluorophenyl)sulfonyl]-1,2,3,4,5,6-hexahydroazepino[4,5-b]indole,
 9-[(3,5-difluorophenyl)sulfonyl]-6-methyl-1,2,3,4,5,6-hexahydroazepino[4,5-
 b]indole,
 20 9-[(4-(2-hydroxyethoxy)phenyl)sulfonyl]-6-methyl-1,2,3,4,5,6-
 hexahydroazepino[4,5-b]indole,
 3,6-dimethyl-9-(phenylsulfonyl)-1,2,3,4,5,6-hexahydroazepino[4,5-b]indole,
 3-methyl-9-(phenylsulfonyl)-1,2,3,4,5,6-hexahydroazepino[4,5-b]indole and
 9-[(4-fluorophenyl)sulfonyl]-3-isopropyl-6-methyl-1,2,3,4,5,6-
 25 hexahydroazepino[4,5-b]indole.

17. A 9-arylsulfone (XII) according to claim 1 where the substituted 9-arylsulfone is
 selected from the group consisting of:

1-methyl-9-(phenylsulfonyl)-1,2,3,4,5,6-hexahydroazepino[4,5-b]indole,
 30 2-methyl-9-(phenylsulfonyl)-1,2,3,4,5,6-hexahydroazepino[4,5-b]indole,
 4-methyl-9-(phenylsulfonyl)-1,2,3,4,5,6-hexahydroazepino[4,5-b]indole,
 5-methyl-9-(phenylsulfonyl)-1,2,3,4,5,6-hexahydroazepino[4,5-b]indole,
 9-[(4-fluorophenyl)sulfonyl]-1-methyl-1,2,3,4,5,6-hexahydroazepino[4,5-b]indole,
 9-[(4-fluorophenyl)sulfonyl]-2-methyl-1,2,3,4,5,6-hexahydroazepino[4,5-b]indole,

- 9-[(4-fluorophenyl)sulfonyl]-4-methyl-1,2,3,4,5,6-hexahydroazepino[4,5-b]indole,
9-[(4-fluorophenyl)sulfonyl]-5-methyl-1,2,3,4,5,6-hexahydroazepino[4,5-b]indole,
1,6-dimethyl-9-(phenylsulfonyl)-1,2,3,4,5,6-hexahydroazepino[4,5-b]indole,
2,6-dimethyl-9-(phenylsulfonyl)-1,2,3,4,5,6-hexahydroazepino[4,5-b]indole,
5 4,6-dimethyl-9-(phenylsulfonyl)-1,2,3,4,5,6-hexahydroazepino[4,5-b]indole,
5,6-dimethyl-9-(phenylsulfonyl)-1,2,3,4,5,6-hexahydroazepino[4,5-b]indole,
9-[(4-fluorophenyl)sulfonyl]-1,6-dimethyl-1,2,3,4,5,6-hexahydroazepino[4,5-
b]indole,
9-[(4-fluorophenyl)sulfonyl]-2,6-dimethyl-1,2,3,4,5,6-hexahydroazepino[4,5-
10 b]indole,
9-[(4-fluorophenyl)sulfonyl]-4,6-dimethyl-1,2,3,4,5,6-hexahydroazepino[4,5-
b]indole,
9-[(4-fluorophenyl)sulfonyl]-5,6-dimethyl-1,2,3,4,5,6-hexahydroazepino[4,5-
b]indole,
15 9-[(3,5-difluorophenyl)sulfonyl]-1-methyl-1,2,3,4,5,6-hexahydroazepino[4,5-
b]indole,
9-[(3,5-difluorophenyl)sulfonyl]-2-methyl-1,2,3,4,5,6-hexahydroazepino[4,5-
b]indole,
9-[(3,5-difluorophenyl)sulfonyl]-4-methyl-1,2,3,4,5,6-hexahydroazepino[4,5-
20 b]indole,
9-[(3,5-difluorophenyl)sulfonyl]-5-methyl-1,2,3,4,5,6-hexahydroazepino[4,5-
b]indole,
9-[(3,5-difluorophenyl)sulfonyl]-1,6-dimethyl-1,2,3,4,5,6-hexahydroazepino[4,5-
b]indole,
25 9-[(3,5-difluorophenyl)sulfonyl]-2,6-dimethyl-1,2,3,4,5,6-hexahydroazepino[4,5-
b]indole,
9-[(3,5-difluorophenyl)sulfonyl]-4,6-dimethyl-1,2,3,4,5,6-hexahydroazepino[4,5-
b]indole,
9-[(3,5-difluorophenyl)sulfonyl]-5,6-dimethyl-1,2,3,4,5,6-hexahydroazepino[4,5-
30 b]indole.

18. A thio ether of formula (III)




5 where R_9 and R_x are as defined in claim 1.

19. A thio ether according to claim 18 where R_9 is selected from the group consisting of -H, -F, -Cl, C_1 - C_3 alkyl, C_1 - C_3 alkoxy and $-CF_3$ and where R_x is selected from the group consisting of -H, -F and -Cl.

10


20. An amine of formula (IV)



where R_9 and R_x are as defined in claim 1.

15 21. An amine according to claim 20 where R_9 and R_x are as defined in claim 19.

22. A hydrazine of formula (V)




where R_9 and R_x are as defined in claim 1.

20

23. A hydrazine according to claim 22 where R_9 and R_x are as defined in claim 19.

24. A compound of formula (VII)




where PG is selected from the group consisting of ϕ -CH₂-, ϕ -CO-, ϕ -CH₂-CO₂- and -CO-O-C(CH₃)₃ where R₉ and R_x are as defined in claim 1.

5

25. A compound according to claim 24 where PG is ϕ -CH₂- or ϕ -CO- and where R₉ and R_x are as defined in claim 19.

26. A protected 9-arylsulfone of formula (VIII)



10


where PG is as defined in claim 24 and R₉ and R_x are as defined in claim 1.

27. A protected 9-arylsulfone according to claim 26 where PG is as defined in claim 25 and where R₉ and R_x are as defined in claim 19.

15

28. A method of treating a human who has a condition selected from the group consisting of anxiety, depression, schizophrenia, stress related disease, panic, a phobia, obsessive compulsive disorder, obesity, post-traumatic stress syndrome who is in need of such treatment which comprises administering an effective amount of a 9-arylsulfone of the formula (XII)

20



where R₃ is:

(1) -H,

(2) C₁-C₄ alkyl,

(3) C₀-C₄-φ where the -φ substituent is optionally substituted with 1 or 2

(a) -F, -Cl, -Br, -I,

(b) -O-R_{3.1} where R_{3.1} is:

-H,

C₁-C₄ alkyl,

-φ,

(c) -CF₃,

(d) -CO-NR_{3.2}R_{3.3} where R_{3.2} and R_{3.3} are -H and C₁-C₄ alkyl, and where R_{3.2}

and R_{3.3} are taken with the attached nitrogen atom to form a ring selected from the group consisting of 1-pyrrolidinyl, 1-piperazinyl and 1-morpholinyl,

(e) -NH-SO₂-R_{3.4} where R_{3.4} is -H and C₁-C₄ alkyl,

(f) -NR_{3.2}R_{3.3} where R_{3.2} and R_{3.3} are as defined above,

(g) -NR_{3.4}-CO-R_{3.4} where R_{3.4} is as defined above,

(h) -SO₂-NR_{3.2}R_{3.3} where R_{3.2} and R_{3.3} are as defined above,

(i) -C≡N,

(j) -NO₂,

where R_N is:

(1) -H,

(2) C₁-C₄ alkyl,

(3) C₀-C₄-φ where the -φ substituent is optionally substituted with 1 or 2

(a) -F, -Cl, -Br, -I,

(b) -O-R_{N.1} where R_{N.1} is

-H,

C₁-C₄ alkyl,

-φ,

(c) -CF₃,

(d) -CO-NR_{N.2}R_{N.3} where R_{N.2} and R_{N.3} are -H and C₁-C₄ alkyl, and where

R_{N.2} and R_{N.3} are taken with the attached nitrogen atom to form a ring selected from the group consisting of 1-pyrrolidinyl, 1-piperazinyl and 1-morpholinyl,

(e) -NH-SO₂-R_{N.4} where R_{N.4} is -H and C₁-C₄ alkyl,

(f) -NR_{N.2}R_{N.3} where R_{N.2} and R_{N.3} are as defined above,

(g) -NR_{N.4}-CO-R_{N.4} where R_{N.4} is as defined above,

(h) $-\text{SO}_2-\text{NR}_{\text{N-2}}\text{R}_{\text{N-3}}$ where $\text{R}_{\text{N-2}}$ and $\text{R}_{\text{N-3}}$ are as defined above,

(i) $-\text{C}\equiv\text{N}$,

(j) $-\text{NO}_2$,

where R_X is:

5

(1) $-\text{H}$

(2) $-\text{F}$, $-\text{Cl}$, $-\text{Br}$, $-\text{I}$,

(3) $-\text{O}-\text{R}_{\text{X-1}}$ where $\text{R}_{\text{X-1}}$ is:

$-\text{H}$,

C_1-C_4 alkyl,

10

$-\phi$,

(4) $-\text{CF}_3$,

(5) $-\text{CO}-\text{NR}_{\text{X-2}}\text{R}_{\text{X-3}}$ where $\text{R}_{\text{X-2}}$ and $\text{R}_{\text{X-3}}$ are as defined above,

(6) $-\text{NH}-\text{SO}_2-\text{R}_{\text{X-4}}$ where $\text{R}_{\text{X-4}}$ is as defined above,

(7) $-\text{NR}_{\text{X-2}}\text{R}_{\text{X-3}}$ where $\text{R}_{\text{X-2}}$ and $\text{R}_{\text{X-3}}$ are as defined above,

15

(8) $-\text{NR}_{\text{X-4}}-\text{CO}-\text{R}_{\text{X-4}}$ where $\text{R}_{\text{X-4}}$ is as defined above,

(9) $-\text{SO}_2-\text{NR}_{\text{X-2}}\text{R}_{\text{X-3}}$ where $\text{R}_{\text{X-2}}$ and $\text{R}_{\text{X-3}}$ are as defined above,

(10) $-\text{C}\equiv\text{N}$,

(11) $-\text{NO}_2$;

where R_9 is:

20

(1) $-\text{H}$,

(2) $-\text{F}$, $-\text{Cl}$,

(3) C_1-C_4 alkyl,

(4) C_1-C_3 alkoxy,

(5) $-\text{CF}_3$,

25

(6) $\text{C}_0-\text{C}_4-\phi$ where the $-\phi$ substituent is optionally substituted with 1 or 2

(a) $-\text{F}$, $-\text{Cl}$, $-\text{Br}$, $-\text{I}$,

(b) $-\text{O}-\text{R}_{9-1}$ where R_{9-1} is:

$-\text{H}$,

C_1-C_4 alkyl,

30

$-\phi$,

(c) $-\text{CF}_3$,

(d) $-\text{CO}-\text{NR}_{9-2}\text{R}_{9-3}$ where R_{9-2} and R_{9-3} are $-\text{H}$ and C_1-C_4 alkyl, and where

R_{9.2} and R_{9.3} are taken with the attached nitrogen atom to form a ring selected from the group consisting of 1-pyrrolidinyl, 1-piperazinyl and 1-morpholinyl,

- (e) -NH-SO₂-R_{9.4} where R_{9.4} is -H and C₁-C₄ alkyl,
- (f) -NR_{9.2}R_{9.3} where R_{9.2} and R_{9.3} are as defined above,
- (g) -NR_{9.4}-CO-R_{9.4} where R_{9.4} is as defined above,
- (h) -SO₂-NR_{9.2}R_{9.3} where R_{9.2} and R_{9.3} are as defined above,
- (i) -C≡N,
- (j) -NO₂
- (7) -OR_{9.1} where R_{9.1} is as defined above,
- (8) -CO-NR_{9.2}R_{9.3} where R_{9.2} and R_{9.3} are as defined above,
- (9) -NR_{9.2}R_{9.3} where R_{9.2} and R_{9.3} are as defined above,
- (10) -NH-SO₂-R_{9.4} where R_{9.4} is as defined above,
- (11) -NH-CO₂-R_{9.2} where R_{9.2} is as defined above,

and pharmaceutically acceptable salts thereof.

29. A method of treating a human according to claim 28 where the condition is anxiety or depression.

30. A method of treating a human according to claim 28 where the administered is orally, sublingually, transdermally and parenterally.

31. A method of treating a human according to claim 30 where the administration is oral.

32. A method of treating a human according to claim 28 where the administration is in divided doses either two, three or four times daily.

33. A method of treating a human according to claim 28 where the effective amount is from about 0.1 to about 50 mg/kg/day.

34. A method of treating a human according to claim 33 where the effective amount is from about 0.1 to about 10 mg/kg/day.

35. A method of treating a human according to claim 28 where the 9-arylsulfone of the formula (XII) is selected from the group consisting of

- 9-(phenylsulfonyl)-1,2,3,4,5,6-hexahydroazepino[4,5-b]indole,
 9-[(4-fluorophenyl)sulfonyl]-1,2,3,4,5,6-hexahydroazepino[4,5-b]indole,
 9-[(4-methylphenyl)sulfonyl]-1,2,3,4,5,6-hexahydroazepino[4,5-b]indole,
 9-[(4-methoxyphenyl)sulfonyl]-1,2,3,4,5,6-hexahydroazepino[4,5-b]indole,
 5 9-[(3-fluorophenyl)sulfonyl]-1,2,3,4,5,6-hexahydroazepino[4,5-b]indole,
 9-[(3-methoxyphenyl)sulfonyl]-1,2,3,4,5,6-hexahydroazepino[4,5-b]indole,
 9-[(4-trifluoromethylphenyl)sulfonyl]-1,2,3,4,5,6-hexahydroazepino[4,5-b]indole,
 6-ethyl-9-(phenylsulfonyl)-1,2,3,4,5,6-hexahydroazepino[4,5-b]indole,
 6-ethyl-9-[(4-fluorophenyl)sulfonyl]-1,2,3,4,5,6-hexahydroazepino[4,5-b]indole,
 10 6-methyl-9-[(4-fluorophenyl)sulfonyl]-1,2,3,4,5,6-hexahydroazepino[4,5-b]indole,
 6-methyl-9-[(4-trifluoromethylphenyl)sulfonyl]-1,2,3,4,5,6-hexahydroazepino[4,5-
 b]indole,
 6-ethyl-9-[(4-trifluoromethylphenyl)sulfonyl]-1,2,3,4,5,6-hexahydroazepino[4,5-
 b]indole,
 15 6-methyl-9-(phenylsulfonyl)-1,2,3,4,5,6-hexahydroazepino[4,5-b]indole,
 9-[(3,4-difluorophenyl)sulfonyl]-1,2,3,4,5,6-hexahydroazepino[4,5-b]indole,
 9-[(3,5-difluorophenyl)sulfonyl]-1,2,3,4,5,6-hexahydroazepino[4,5-b]indole,
 9-[(3,5-difluorophenyl)sulfonyl]-6-methyl-1,2,3,4,5,6-hexahydroazepino[4,5-
 b]indole,
 20 9-[(4-(2-hydroxyethoxy)phenyl)sulfonyl]-6-methyl-1,2,3,4,5,6-
 hexahydroazepino[4,5-b]indole,
 3,6-dimethyl-9-(phenylsulfonyl)-1,2,3,4,5,6-hexahydroazepino[4,5-b]indole,
 3-methyl-9-(phenylsulfonyl)-1,2,3,4,5,6-hexahydroazepino[4,5-b]indole and
 9-[(4-fluorophenyl)sulfonyl]-3-isopropyl-6-methyl-1,2,3,4,5,6-
 25 hexahydroazepino[4,5-b]indole.

36. A method of treating a human according to claim 35 where the 9-arylsulfone of the formula (XII) is 6-methyl-9-(phenylsulfonyl)-1,2,3,4,5,6-hexahydroazepino[4,5-b]indole.

- 30 37. A method of treating a human according to claim 28 where the 9-arylsulfone of the formula (XII) is selected from the group consisting of

1-methyl-9-(phenylsulfonyl)-1,2,3,4,5,6-hexahydroazepino[4,5-b]indole,
 2-methyl-9-(phenylsulfonyl)-1,2,3,4,5,6-hexahydroazepino[4,5-b]indole,
 4-methyl-9-(phenylsulfonyl)-1,2,3,4,5,6-hexahydroazepino[4,5-b]indole,

5-methyl-9-(phenylsulfonyl)-1,2,3,4,5,6-hexahydroazepino[4,5-b]indole,
9-[(4-fluorophenyl)sulfonyl]-1-methyl-1,2,3,4,5,6-hexahydroazepino[4,5-b]indole,
9-[(4-fluorophenyl)sulfonyl]-2-methyl-1,2,3,4,5,6-hexahydroazepino[4,5-b]indole,
9-[(4-fluorophenyl)sulfonyl]-4-methyl-1,2,3,4,5,6-hexahydroazepino[4,5-b]indole,
5 9-[(4-fluorophenyl)sulfonyl]-5-methyl-1,2,3,4,5,6-hexahydroazepino[4,5-b]indole,
1,6-dimethyl-9-(phenylsulfonyl)-1,2,3,4,5,6-hexahydroazepino[4,5-b]indole,
2,6-dimethyl-9-(phenylsulfonyl)-1,2,3,4,5,6-hexahydroazepino[4,5-b]indole,
4,6-dimethyl-9-(phenylsulfonyl)-1,2,3,4,5,6-hexahydroazepino[4,5-b]indole,
5,6-dimethyl-9-(phenylsulfonyl)-1,2,3,4,5,6-hexahydroazepino[4,5-b]indole,
10 9-[(4-fluorophenyl)sulfonyl]-1,6-dimethyl-1,2,3,4,5,6-hexahydroazepino[4,5-
b]indole,
9-[(4-fluorophenyl)sulfonyl]-2,6-dimethyl-1,2,3,4,5,6-hexahydroazepino[4,5-
b]indole,
9-[(4-fluorophenyl)sulfonyl]-4,6-dimethyl-1,2,3,4,5,6-hexahydroazepino[4,5-
15 b]indole,
9-[(4-fluorophenyl)sulfonyl]-5,6-dimethyl-1,2,3,4,5,6-hexahydroazepino[4,5-
b]indole,
9-[(3,5-difluorophenyl)sulfonyl]-1-methyl-1,2,3,4,5,6-hexahydroazepino[4,5-
b]indole,
20 9-[(3,5-difluorophenyl)sulfonyl]-2-methyl-1,2,3,4,5,6-hexahydroazepino[4,5-
b]indole,
9-[(3,5-difluorophenyl)sulfonyl]-4-methyl-1,2,3,4,5,6-hexahydroazepino[4,5-
b]indole,
9-[(3,5-difluorophenyl)sulfonyl]-5-methyl-1,2,3,4,5,6-hexahydroazepino[4,5-
25 b]indole,
9-[(3,5-difluorophenyl)sulfonyl]-1,6-dimethyl-1,2,3,4,5,6-hexahydroazepino[4,5-
b]indole,
9-[(3,5-difluorophenyl)sulfonyl]-2,6-dimethyl-1,2,3,4,5,6-hexahydroazepino[4,5-
b]indole,
30 9-[(3,5-difluorophenyl)sulfonyl]-4,6-dimethyl-1,2,3,4,5,6-hexahydroazepino[4,5-
b]indole,
9-[(3,5-difluorophenyl)sulfonyl]-5,6-dimethyl-1,2,3,4,5,6-hexahydroazepino[4,5-
b]indole.

FOR RELEASE